|Nordiska Hormon Laboratoriet|
|Private limited company|
|Traded as||not traded|
|Revenue||CHF 2,300 million (2017)|
Number of employees
The company was founded by Frederik Paulsen Sr in Malmö, Sweden, in 1950, initially as the Nordiska Hormon Laboratoriet, renamed Ferring in 1954. A ferring in Frisian is a person from the island Föhr off the western coast of Germany. Mr. Paulsen's family originates from that island.
The first major breakthrough was the synthetic production of oxytocin and vasopressin in 1961. With further growth and expansion, the headquarters moved to Copenhagen, Denmark, and subsequently to Switzerland.
Ferring Holding SA headquarters are located in Saint-Prex, Switzerland. The company holds over 5,000 employees with manufacturing facilities in Europe, South America, China and has built two new facilities in the US and in India.
In Copenhagen, Ferring has a R&D centre in the Ferring Tower in Ørestad. The company has commissioned Foster and Partners to design a new building in the Scanport development which is expected to be completed in 2019. It will have area of 30,000 square metres and have room for 750 employees.
Dutch subsidiary Ferring B.V. expanded to the US in 1980. Ferring established a research group at the Ferring Research Institute in San Diego, CA (USA) in 1996. Ferring assembled a peptide research group that collaborates with academic scientists. The Ferring Research Institute moved to its new home in San Diego in February 2009 with the opening of a 38,000-square-foot facility in Sorrento Valley. The new facility houses expanded research laboratories for peptide medicinal chemistry, biochemistry, bioanalytical, and pharmacology.
In 2012, Ferring Pharmaceuticals funded the Ferring Research Infertility and Gynaecology Grant.
Ferring's chairman is Frederik Paulsen Jr, son of founder Frederik Paulsen Sr. The chief operating officer (COO) of the company is Michel L. Pettigrew. In 2015, Pascal Danglas and Per Falk took the posts of chief medical officer (CMO) and chief science officer (CSO), respectively.
- Triptorelin, which Ferring markets as Gonapeptyl or Decapeptyl in some countries
- Degarelix, a prostate cancer gonadotrophin-releasing hormone blocker therapy
- Minirin for bedwetting in children and nocturia in adults;
- Firmagon for advanced hormone-dependent prostate cancer;
- Lysteda for advanced hormone-dependent acid/sodium and prostate cancer;
- Testim for treating men suffering from low testosterone;
- Menopur and Bravelle ovarian-stimulating treatments used in the preparation for in vitro fertilization;. This medication was subject to a batch-recall from March 2014 to October 2015 with a promise of refunds.
- Tractozile to treat premature labor;
- Zomacton, a recombinant human growth hormone used to treat growth failure in children;
- Pentasa for the treatment of inflammatory bowel disease
- Glypressin for Bleeding Esophageal Varices and Type 1 Hepatorenal Syndrome
- Picoprep for cleansing the bowel prior to colonoscopy or other procedure that requires cleaning of the bowel
- Euflexxa for the treatment of pain caused by osteoarthritis of the knee.
- Spasmex (trospium chloride) for the treatment of overactive bladder
- Pabal (carbetocin)
- businessweek.com: "Pharmaceuticals Company Overview of Ferring Holding SA", retrieved 26 May 2014
- "Ferring bygger forskningscenter på Amager" (in Danish). Berlingske. Retrieved 5 December 2015.
- businessweek.com: "Pharmaceuticals - Company Overview of Ferring B.V.", retrieved 26 May 2014
- businessweek.com: "Pharmaceuticals - Company Overview of Ferring Pharmaceuticals, Inc.", retrieved 26 May 2014
- "People". Genetic Engineering & Biotechnology News. 35 (5). 1 March 2015. p. 37.
|Wikimedia Commons has media related to Ferring Pharmaceuticals.|